Comparison of omapatrilat and enalapril in patients with chronic heart failure: The omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE)

Circulation

Volumn 106, Issue 8, 2002, Pages 920-926

  Packer, Milton ^a   Califf, Robert M ^a   Konstam, Marvin A ^a   Krum, Henry ^a   McMurray, John J ^a   Rouleau, Jean Lucien ^a   Swedberg, Karl ^a  

^a College of Physicians and Surgeons ^*  (United States)

Author keywords

Angiotensin converting enzyme inhibitors; Heart failure; Omapatrilat

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; OMAPATRILAT;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; COUGHING; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EDEMA; FATIGUE; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYALGIA; NAUSEA; NEPHROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VERTIGO; VOMITING;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHRONIC DISEASE; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; ENALAPRIL; ENDPOINT DETERMINATION; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; NEPRILYSIN; PROTEASE INHIBITORS; PYRIDINES; THIAZEPINES;

EID: 0037143601     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000029801.86489.50     Document Type: Article

References (20)

1. Atrial natriuretic peptide in heart failure
2. Functional effects of endogenous bradykinin in congestive heart failure
3. Novel neuropeptides in the pathophysiology of heart failure: Adrenomedullin and endothelin-1
4. Cell surface metallopeptidases involved in blood pressure regulation: Structure, inhibition and clinical perspectives
5. Candoxatril improves exercise capacity in patients with chronic heart failure receiving angiotensin converting enzyme inhibition
6. Neurohormonal inhibition and hemodynamic unloading during prolonged inhibition of ANF degradation in patients with severe chronic heart failure
7. New dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme: Rational design, bioavailability, and pharmacological responses in experimental hypertension
8. Combined neutral endopeptidase and angiotensin-converting enzyme inhibition in heart failure: Role of natriuretic peptides and angiotensin II
9. Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril
10. Omapatrilat versus lisinopril: Efficacy and neurohormonal profile in salt-sensitive hypertensive patients
11. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial
12. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
13. Discrete sequential boundaries of clinical trials
14. Renal response to acute neutral endopeptidase inhibition in mild and severe experimental heart failure
15. Vasodilatory effects of B-type natriuretic peptide are impaired in patients with chronic heart failure
16. Potent and long-lasting vasodilatory effects of adrenomedullin in humans. Comparisons between normal subjects and patients with chronic heart failure
17. Pharmacodynamics and pharmacokinetics of omapatrilat in heart failure
18. Pharmacodynamic effects of dual neutral endopeptidase-angiotensin-converting enzyme inhibition versus angiotensin-converting enzyme inhibition in humans
19. Beneficial renal and hemodynamic effects of omapatrilat in mild and severe heart failure
20. Plasma exudation in conscious dogs with experimental heart failure